The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types |
| |
| Authors: | Hermann Einsele MD Hossein Borghaei DO Robert Z Orlowski MD Marion Subklewe MD Gail J Roboz MD Gerhard Zugmaier MD Peter Kufer MD Karim Iskander MD Hagop M Kantarjian MD |
| |
| Affiliation: | 1. Department of Internal Medicine II, Universität Würzburg, Würzburg, Germany;2. Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania;3. Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas;4. Department of Medicine III, University Hospital, Ludwig-Maximilians University Munich, Munich, Germany;5. Weill Cornell Medicine, Division of Hematology and Oncology, The New York Presbyterian Hospital, New York, New York;6. Amgen Research (Munich) GmbH, Munich, Germany;7. Amgen Inc., Thousand Oaks, California;8. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| |
| Abstract: | Immuno-oncology therapies engage the immune system to treat cancer. BiTE (bispecific T-cell engager) technology is a targeted immuno-oncology platform that connects patients' own T cells to malignant cells. The modular nature of BiTE technology facilitates the generation of molecules against tumor-specific antigens, allowing off-the-shelf immuno-oncotherapy. Blinatumomab was the first approved canonical BiTE molecule and targets CD19 surface antigens on B cells, making blinatumomab largely independent of genetic alterations or intracellular escape mechanisms. Additional BiTE molecules in development target other hematologic malignancies (eg, multiple myeloma, acute myeloid leukemia, and B-cell non-Hodgkin lymphoma) and solid tumors (eg, prostate cancer, glioblastoma, gastric cancer, and small-cell lung cancer). BiTE molecules with an extended half-life relative to the canonical BiTE molecules are also being developed. Advances in immuno-oncology made with BiTE technology could substantially improve the treatment of hematologic and solid tumors and offer enhanced activity in combination with other treatments. |
| |
| Keywords: | B cell blinatumomab hematologic malignancies T cell tumor-specific antigen |
|
|
